The global canine atopic dermatitis treatment market accounted for USD 1.14 billion in 2023 and is expected to reach at USD 1.64 billion by 2034 with a CAGR of 3.36% during the forecast period 2024-2034. The market will grow as a result of factors such as rising pet ownership and humanization, increasing prevalence of canine atopic dermatitis, advances in veterinary medicine, increased awareness and education, and a focus on better treatment options.
New treatments like monoclonal antibodies are being developed and introduced to the market. In comparison to conventional treatments, these drugs provide tailored therapy with maybe fewer adverse effects. To produce even more practical and efficient therapies for canine atopic dermatitis, pharmaceutical companies are actively engaged in research and development. Market expansion is fueled by this ongoing innovation. For instance, in December 2022, Zoetis released encouraging topline findings from a pivotal field trial assessing the efficacy and safety of a novel medication for atopic dermatitis in dogs.
By drug class, the immunosuppressant segment accounted for the highest revenue-grossing segment in the global canine atopic dermatitis treatment market in 2023 owing to the high efficacy in managing severe symptoms and inflammation, driving demand among veterinarians and pet owners seeking effective treatment options for canine atopic dermatitis. For instance, Elanco announced in January 2023 the introduction of a novel version of an established drug intended to treat atopic dermatitis in dogs. Additionally, the monoclonal antibodies segment is predicted to grow at the fastest CAGR during the forecast period owing to the rapid advancements in biotechnology, which have led to the development of targeted and personalized therapies, offering superior efficacy with fewer side effects compared to traditional treatments, thus driving adoption among veterinarians and pet owners seeking innovative solutions for canine atopic dermatitis management.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global canine atopic dermatitis treatment market in 2023 owing to the convenience and ease of administration, making oral medications a preferred choice for pet owners and veterinarians seeking effective and practical treatment options for managing canine atopic dermatitis. For instance, Elanco announced in January 2023 the introduction of a novel version of an established drug intended to treat atopic dermatitis in dogs. Additionally, the injectable segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for targeted and long-lasting treatment options, driving demand among veterinarians and pet owners seeking efficient and convenient solutions for managing canine atopic dermatitis with reduced frequency of administration.
By distribution channel, the veterinary hospitals and clinics segment accounted for the highest revenue-grossing segment in the global canine atopic dermatitis treatment market in 2023 owing to the increasing awareness and availability of specialized care, leading pet owners to seek professional veterinary services for accurate diagnosis, personalized treatment plans, and comprehensive management of canine atopic dermatitis, thereby driving revenue growth in this segment. For instance, Bayer reported in September 2023 that recruitment in a Phase III clinical trial assessing a potential therapeutic method for canine atopic dermatitis has concluded. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience and accessibility, as pet owners increasingly prefer the ease of ordering medications online, coupled with a growing trend towards e-commerce for pet healthcare products, driving the rapid growth of online pharmacies in the canine atopic dermatitis treatment market.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of canine atopic dermatitis, advanced veterinary healthcare infrastructure, increasing pet ownership rates, and robust research and development activities, driving demand for innovative treatment options and contributing to the dominant revenue share in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about pet healthcare, expanding pet ownership, improving economic conditions, and increasing investments in veterinary infrastructure and research, driving the demand for canine atopic dermatitis treatments and fueling the rapid growth of the Asia Pacific market. For instance, Boehringer Ingelheim stated in November 2022 that it was acquiring a biotechnology company that specialized in the development of immunotherapies for animal allergy illnesses, such as atopic dermatitis in dogs.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
New treatments like monoclonal antibodies are being developed and introduced to the market. In comparison to conventional treatments, these drugs provide tailored therapy with maybe fewer adverse effects. To produce even more practical and efficient therapies for canine atopic dermatitis, pharmaceutical companies are actively engaged in research and development. Market expansion is fueled by this ongoing innovation. For instance, in December 2022, Zoetis released encouraging topline findings from a pivotal field trial assessing the efficacy and safety of a novel medication for atopic dermatitis in dogs.
By drug class, the immunosuppressant segment accounted for the highest revenue-grossing segment in the global canine atopic dermatitis treatment market in 2023 owing to the high efficacy in managing severe symptoms and inflammation, driving demand among veterinarians and pet owners seeking effective treatment options for canine atopic dermatitis. For instance, Elanco announced in January 2023 the introduction of a novel version of an established drug intended to treat atopic dermatitis in dogs. Additionally, the monoclonal antibodies segment is predicted to grow at the fastest CAGR during the forecast period owing to the rapid advancements in biotechnology, which have led to the development of targeted and personalized therapies, offering superior efficacy with fewer side effects compared to traditional treatments, thus driving adoption among veterinarians and pet owners seeking innovative solutions for canine atopic dermatitis management.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global canine atopic dermatitis treatment market in 2023 owing to the convenience and ease of administration, making oral medications a preferred choice for pet owners and veterinarians seeking effective and practical treatment options for managing canine atopic dermatitis. For instance, Elanco announced in January 2023 the introduction of a novel version of an established drug intended to treat atopic dermatitis in dogs. Additionally, the injectable segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for targeted and long-lasting treatment options, driving demand among veterinarians and pet owners seeking efficient and convenient solutions for managing canine atopic dermatitis with reduced frequency of administration.
By distribution channel, the veterinary hospitals and clinics segment accounted for the highest revenue-grossing segment in the global canine atopic dermatitis treatment market in 2023 owing to the increasing awareness and availability of specialized care, leading pet owners to seek professional veterinary services for accurate diagnosis, personalized treatment plans, and comprehensive management of canine atopic dermatitis, thereby driving revenue growth in this segment. For instance, Bayer reported in September 2023 that recruitment in a Phase III clinical trial assessing a potential therapeutic method for canine atopic dermatitis has concluded. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience and accessibility, as pet owners increasingly prefer the ease of ordering medications online, coupled with a growing trend towards e-commerce for pet healthcare products, driving the rapid growth of online pharmacies in the canine atopic dermatitis treatment market.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of canine atopic dermatitis, advanced veterinary healthcare infrastructure, increasing pet ownership rates, and robust research and development activities, driving demand for innovative treatment options and contributing to the dominant revenue share in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about pet healthcare, expanding pet ownership, improving economic conditions, and increasing investments in veterinary infrastructure and research, driving the demand for canine atopic dermatitis treatments and fueling the rapid growth of the Asia Pacific market. For instance, Boehringer Ingelheim stated in November 2022 that it was acquiring a biotechnology company that specialized in the development of immunotherapies for animal allergy illnesses, such as atopic dermatitis in dogs.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Drug Class, Route of Administration, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Canine Atopic Dermatitis Treatment Market Report 2023 - 2034
Canine Atopic Dermatitis Treatment Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Corticosteroids
- Immunosuppressants
- Antibiotics
- Antihistamines
- Emollients
- Essential Fatty Acids
- Antipruritic
- Monoclonal Antibodies
Canine Atopic Dermatitis Treatment Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Topical
- Oral
- Injectable
Canine Atopic Dermatitis Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Veterinary Hospitals
- Veterinary Clinics
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
Canine Atopic Dermatitis Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Canine Atopic Dermatitis Treatment Market: Drug Class Estimates & Trend Analysis
8. Canine Atopic Dermatitis Treatment Market: Route of Administration Estimates & Trend Analysis
9. Canine Atopic Dermatitis Treatment Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Canine Atopic Dermatitis Treatment Market
12. Europe Global Canine Atopic Dermatitis Treatment Market
13. Asia Pacific Global Canine Atopic Dermatitis Treatment Market
14. Latin America Global Canine Atopic Dermatitis Treatment Market
15. MEA Global Canine Atopic Dermatitis Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Zoetis Inc.
- Elanco Animal Health Incorporated
- Bayer AG
- Boehringer Ingelheim Animal Health
- Virbac
- Vetoquinol S.A.
- Ceva Santé Animale
- Dechra Pharmaceuticals PLC
- Novartis Animal Health Inc. (now part of Elanco)
- Merck Animal Health
- Idexx Laboratories Inc.
- Merial Limited (now part of Boehringer Ingelheim)
- Apoquel (Zoetis)
- Royal Canin
- Dermoscent Biofen.
